Doxorubicin liposome with CapOX and bevacizumab for colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (doxorubicin liposome, capecitabine, oxaliplatin, and bevacizumab) as a first treatment for advanced colorectal cancer that has a specific SMAD4 gene mutation. The goal is to see if this combination shrinks tumors and is safe for patients who have not had chemotherapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have advanced colorectal cancer that cannot be removed by surgery
- Your tumor must have a specific mutation called SMAD4 R361H or C
- Your tumor must not be the type that is mismatch repair deficient or MSI-high
- If your cancer is on the left side or in the rectum, it must not be RAS wild-type
- You must not have had chemotherapy for this cancer before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
This study tests a combination of several cancer drugs (irinotecan, capecitabine, bevacizumab, and camrelizumab) in people with metastatic colorectal cancer who have already tried at least one prior treatment. The goal is to see if these drugs work better together for patients who don't have certain genetic features.
This Phase 2 trial tests whether bevacizumab plus oxaliplatin and TAS-102 works better and is safe as the first treatment for advanced colorectal (colon/rectum) cancer. You may be asked to meet specific health and blood-test requirements and avoid other cancer treatments during the study.
This trial is testing a combination of three drugs (liposomal irinotecan, capecitabine, and bevacizumab) for people with metastatic colorectal cancer whose first-line treatment failed. The goal is to see if this combo works better as a second option.
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
This trial tests a combination of two targeted therapies (QL1706 and bevacizumab) plus standard chemotherapy for people with a specific form of metastatic colorectal cancer that has a BRAF V600E mutation and is MSS/pMMR. The goal is to see if this triplet works better than standard treatment alone.
Hear when a new Advanced Colorectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.